The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Cantor Fitzgerald has reaffirmed its 'Neutral' rating on Amgen Inc. (AMGN) with a price target of $350.00 as the company prepares for its Q1 2026 earnings release. Analysts anticipate that key commercial drivers, specifically Repatha and Uplizna, will exceed market expectations in the upcoming financial report. The biotech giant recently announced successful Phase 3 trial results for TEPEZZA, a treatment for Thyroid Eye Disease, further bolstering investor confidence. While Cantor Fitzgerald remains cautious, other firms like William Blair and RBC Capital have reiterated 'Outperform' ratings following the clinical success. The combination of strong product momentum and positive trial outcomes provides a favorable backdrop for the stock. Investors are now closely monitoring the upcoming earnings call for further updates on the company's pipeline and commercial strategy.
Sign up free to access this content
Create Free Account